HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $75
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $90 to $75.
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $90 to $75.